Printer Friendly

Alnylam says givosiran showed sustained clinical activity in Phase 1/2 OLE study.

Alnylam Pharmaceuticals announced that the Company presented updated results from the ongoing Phase 1/2 open-label extension study of givosiran, an investigational RNAi therapeutic, targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria. As of the data cut-off date of June 7, 2018, a robust treatment effect was maintained in givosiran-treated patients with continued dosing in the Phase 1/2 OLE study, with a mean time on treatment of 13.6 months and total time on treatment across the Phase 1 and OLE studies of up to 25 months. Monthly dosing at 2.5 mg/kg led to sustained lowering of aminolevulinic acid and porphobilinogen toward normal levels, with a mean reduction from baseline of 87 and 83 percent, respectively, at 12 months. In patients who received givosiran during the Phase 1 study and continued with givosiran dosing in the OLE study, mean reductions in annualized attack rate of 93 percent and annualized hemin use of 94 percent were observed, relative to pre-treatment results. Similarly, patients in the placebo arm of the Phase 1 study crossing over to givosiran treatment in the OLE study experienced mean reductions in AAR of 95 percent and annualized hemin use of 98 percent. Seven of sixteen patients achieved an AAR of zero with a mean of 11.3 months on treatment; the average AAR during the run-in period for these seven patients was 15.2. Serious adverse events were reported in four patients. Previously reported SAEs included: a patient with an upper extremity deep vein thrombosis, assessed as unlikely related to study drug by the investigator; and one patient who had an anaphylactic reaction after the third dose of givosiran, assessed as definitely related to study drug, which resolved with medical management. New SAEs included: a patient with two episodes of pyrexia related to a suspected Port-a-Cath infection and chlamydia bronchitis, assessed as unlikely related to study drug; and one patient with a change in mental status due to a possible glucocorticoid toxicity from an acute bacterial sinusitis, both of which were assessed as unlikely related to study drug. Adverse events occurring in three or more patients included abdominal pain, fatigue, injection site erythema, nausea, myalgia, diarrhea, headache, and nasopharyngitis. Six patients had injection site reactions, all mild to moderate. No clinically significant increases in liver function tests or lipase levels were noted with continued dosing in the OLE study.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Nov 9, 2018
Previous Article:Cue Biopharma presents foundational data on Immuno-STAT platform and CUE-101.
Next Article:LGI Homes announces $50M stock repurchase program.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters